Role of MAPK and JNK Signaling Pathways in Skin Cancer Progression and Therapeutic Approach
Dermatological Health · 2025
DOI: 10.26689/dh.v2i4.9039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatological Health, 2025. Verfasst von Hamza Khaliq.
Abstract (Originalsprache)
Mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) pathways exhibit complex signal transduction pathways that modulate multiple processes and the deregulated form of MAPK is involved in many types of cancers including skin cancer. These signaling pathways regulate cellular processes such as differentiation, inflammation, cell proliferation, and survival. Moreover, MAPKs are crucial signaling pathways in regulating various cellular processes, including cell proliferation, differentiation, survival, and apoptosis. Their dysregulation is commonly observed in cancer, making them attractive targets for therapeutic intervention. The critical mechanisms and pathways of MAPKs and JNKs in skin cancer including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma are summarized in this review. In addition to providing new insights into MAPK and JNK pathways in cancer progression and proliferation, we also offered the significance of the mechanism of JNK in drug resistance and the association of KLF4 in influencing JNKs for future endeavors to be targeted as therapeutic approaches as understanding the molecular aspects of these signaling pathways are crucial for novel therapeutic breakthroughs.
Zitieren
APA
Khaliq, H. (2025). Role of MAPK and JNK Signaling Pathways in Skin Cancer Progression and Therapeutic Approach. Dermatological Health. https://doi.org/10.26689/dh.v2i4.9039
Vancouver
Khaliq H. Role of MAPK and JNK Signaling Pathways in Skin Cancer Progression and Therapeutic Approach. Dermatological Health. 2025. doi:10.26689/dh.v2i4.9039
BibTeX
@article{Khaliq2025,
author = {Khaliq, Hamza},
title = {Role of MAPK and JNK Signaling Pathways in Skin Cancer Progression and Therapeutic Approach},
journal = {Dermatological Health},
year = {2025},
doi = {10.26689/dh.v2i4.9039}
}
EUVIMED